11/1/2016 11:10:33 AM
TORONTO November 1, 2016 - Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today announced that Charles Wallace, the Company's Chief Financial Officer, is retiring on December 31, 2016 after serving in this capacity since September 2013. Microbix also announced that Jim Currie is joining the Company on November 1, 2016 as the newly appointed Chief Financial Officer.
Mr. Currie was most recently the CFO at SMTC Corporation, a publicly traded global electronics manufacturing services company. Previously, he was Vice-President, Finance at MDS SCIEX, a global leader in life science and analytical technologies.
Vaughn Embro-Pantalony, President and CEO of Microbix commented, "I want to take this opportunity to thank Chuck for his strong financial stewardship; he was instrumental in helping the Company improve its financial position in recent years. And, I welcome Jim to Microbix and to the leadership team. We look forward to working with him as we continue to focus on driving the growth of our Company".
Microbix Biosystems Inc. specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company's pipeline of innovative technologies and products includes LumiSort semen sexing technology for the livestock industries, Kinlytic, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.
comments powered by